The FDA prasugrel review: adjudication of myocardial infarction controversy

Cardiology. 2009;114(2):126-9. doi: 10.1159/000224157. Epub 2009 Jun 5.
No abstract available

Publication types

  • Clinical Trial, Phase III
  • Editorial
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Acute Coronary Syndrome / diagnosis
  • Acute Coronary Syndrome / drug therapy*
  • Acute Coronary Syndrome / mortality*
  • Clopidogrel
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Drug Administration Schedule
  • Female
  • Humans
  • Incidence
  • Male
  • Myocardial Infarction / diagnosis*
  • Myocardial Infarction / drug therapy
  • Myocardial Infarction / mortality*
  • Piperazines / administration & dosage*
  • Piperazines / adverse effects
  • Piperazines / pharmacology
  • Platelet Aggregation Inhibitors / administration & dosage
  • Platelet Aggregation Inhibitors / adverse effects
  • Prasugrel Hydrochloride
  • Prognosis
  • Risk Assessment
  • Survival Analysis
  • Thiophenes / administration & dosage*
  • Thiophenes / adverse effects
  • Thiophenes / pharmacology
  • Ticlopidine / administration & dosage
  • Ticlopidine / adverse effects
  • Ticlopidine / analogs & derivatives
  • Treatment Outcome
  • United States
  • United States Food and Drug Administration

Substances

  • Piperazines
  • Platelet Aggregation Inhibitors
  • Thiophenes
  • Clopidogrel
  • Prasugrel Hydrochloride
  • Ticlopidine